COMP <GO>
XTNT vs MRK // EV/EBITDA & P/E VALUATION
Xtant Medical Holdings Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: XTNT 4
— MRK 8
▲ EV/EBITDA & P/E VALUATION LEADER: XTNT
LAST: $0.29 (+1.54%) • MKT CAP: $40.7M
valuation
3.7x
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XTNT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XTNT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.90% | 74.80% | -11.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | 20.70% | -7.90 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 3.7x | 15.3x | -11.60 | XTNT | /valuation <GO> |
| Free Cash Flow Yield | 24.95% | 3.42% | +21.53 | XTNT | /fcf-yield <GO> |
| Operating Margin | 5.40% | 34.30% | -28.90 | MRK | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.10% | -28.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 14.20% | 1.30% | +12.90 | XTNT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.19 | -4.99 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | XTNT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.9 | 51.7 | -16.76 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.7M | $361.02B | -$360.98B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XTNT REV | MRK REV | XTNT GROSS % | MRK GROSS % | XTNT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $133.9M | $65.01B | 62.9% | 74.8% | $10.2M | $12.36B |
| FY 2024 | $117.3M | $64.17B | 58.2% | 76.3% | -$16.0M | $18.10B |
| FY 2023 | $91.3M | $60.12B | — | — | -$9.5M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XTNT // BETA —
MRK // BETA 0.92